报价延迟最少15分钟:2026/10/18 19:14 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
25.03 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.02/1.32
|
|
企业价值
1.86B
|
| 资产负债 |
|
每股账面净值
1.12
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
105.97M
|
|
每股收益
6.43
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
